The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

EVP Beats Cisplatin for Resectable MIBC

2.

Could CT scans be fueling a future rise in cancer cases, as a new study suggests?

3.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

4.

Next-Generation KRAS G12C Inhibitor Shows 'Robust' Efficacy in Advanced Lung Cancer

5.

Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot